Evidence map›Paper›PMID 36980171›Full record

ReviewCells2023

Human β-Defensins in Diagnosis of Head and Neck Cancers.

Jenna Kompuinen, Mutlu Keskin, Dogukan Yilmaz, Mervi Gürsoy, Ulvi Kahraman Gürsoy

Open access · goldFull text readReview
In one paragraph

Review in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Pioneering Clinical Investigation: Beta Defensin Expression in Patients of Squamous Cell Carcinoma of Oral Cavity as a Forward-Looking Validation for Molecular Treatment.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2025
    Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Jenna KompuinenDepartment of Periodontology, Institute of Dentistry, University of Turku, 20520 Turku, Finland.
Mutlu KeskinOral and Dental Health Department, Altınbaş University, İstanbul 34147, Turkey.ORCID 0000-0002-1045-3930
Dogukan YilmazDepartment of Periodontology, Institute of Dentistry, University of Turku, 20520 Turku, Finland.ORCID 0000-0003-2576-0885
Mervi GürsoyDepartment of Periodontology, Institute of Dentistry, University of Turku, 20520 Turku, Finland.ORCID 0000-0001-8545-6821
Ulvi Kahraman GürsoyDepartment of Periodontology, Institute of Dentistry, University of Turku, 20520 Turku, Finland.ORCID 0000-0002-1225-5751
University of Turku · FIAltınbaş University · TRSakarya University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Head and neck cancers are malignant growths with high death rates, which makes the early diagnosis of the affected patients of utmost importance. Over 90% of oral cavity cancers come from squamous cells, and the tongue, oral cavity, and salivary glands are the most common locations for oral squamous cell carcinoma lesions. Human β-defensins (hBDs), which are mainly produced by epithelial cells, are cationic peptides with a wide antimicrobial spectrum. In addition to their role in antimicrobial defense, these peptides also take part in the regulation of the immune response. Recent studies produced evidence that these small antimicrobial peptides are related to the gene and protein expression profiles of tumors. While the suppression of hBDs is a common finding in head and neck cancer studies, opposite findings were also presented. In the present narrative review, the aim will be to discuss the changes in the hBD expression profile during the onset and progression of head and neck cancers. The final aim will be to discuss the use of hBDs as diagnostic markers of head and neck cancers.

Indexed as

Anti-Infective Agentsbeta-DefensinsCarcinoma, Squamous CellMouth NeoplasmsHumansPeptidesAnti-Infective Agentsbeta-DefensinsPeptidesantimicrobial peptidescancerdiagnosishuman beta-defensinsimmune response

Identifiers

PMID36980171
PMCPMC10047923
OpenAlexW4323568799

What OpenQuestion holds

Textfull text, public
LicenceCC BY
reference markers read8
measurements read8
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.